ArticleMicroorganisms2022
Targeting of Regulators as a Promising Approach in the Search for Novel Antimicrobial Agents.
Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Pangenomic analysis reveals metabolic adaptation ofVirulence · 2026Article
- Fermented Navy Bean-Derived Agents Restore Antibiotic Susceptibility inJournal of microbiology and biotechnology · 2026Article
- Inhibitory Effects onPlants (Basel, Switzerland) · 2024Article
- Adaptive response ofMicrobiology (Reading, England) · 2024Article
- Levofloxacin and Ciprofloxacin Co-Crystals with Flavonoids: Solid-State Investigation for a Multitarget Strategy againstPharmaceutics · 2024Article
- ResR/McdR-regulated protein translation machinery contributes to drug resilience in Mycobacterium tuberculosis.Communications biology · 2023Article
- Editorial: Role of transcription factors and sigma factors in bacterial stress physiology.Frontiers in microbiology · 2023Article
- Insights into the Orchestration of Gene Transcription Regulators inInternational journal of molecular sciences · 2022Review
- Effects of Sub-Minimum Inhibitory Concentrations of Imipenem and Colistin on Expression of Biofilm-Specific Antibiotic Resistance and Virulence Genes inInternational journal of molecular sciences · 2022Article
- Differential Impact of Random GC Tetrad Binding and Chromatin Events on Transcriptional Inhibition by Olivomycin A.International journal of molecular sciences · 2022Article
- Thirty Years of sRNA-Mediated Regulation inInternational journal of molecular sciences · 2022Review
- Regulation of neutrophil myeloperoxidase inhibitor SPIN by the small RNA Teg49 in Staphylococcus aureus.Molecular microbiology · 2022Article
- Targeting the Essential Transcription Factor HP1043 ofFrontiers in molecular biosciences · 2022Article
- Two-component regulatory systems inFrontiers in cellular and infection microbiology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the discovery of penicillin in the first half of the last century, antibiotics have become the pillars of modern medicine for fighting bacterial infections. However, pathogens resistant to antibiotic treatment have increased in recent decades, and efforts to discover new antibiotics have decreased. As a result, it is becoming increasingly difficult to treat bacterial infections successfully, and we look forward to more significant efforts from both governments and the scientific community to research new antibacterial drugs. This perspective article highlights the high potential of bacterial transcriptional and posttranscriptional regulators as targets for developing new drugs. We highlight some recent advances in the search for new compounds that inhibit their biological activity and, as such, appear very promising for treating bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.